Bengaluru, Karnataka, India, November 20, 2017:
Biocon confirms that the U.S. Food and Drug Administration (FDA) has issued an Establishment Inspection Report (EIR) in relation to the cGMP (current Good Manufacturing Practice) inspection of its aseptic drug product facility that was audited between 25th May 3rd Jun 2017. The FDA has classified the outcome of this inspection as VAI (“voluntary action indicated”) and the EIR states that the inspection is closed.
– Company Spokesperson
You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.
Download Company Statement